Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
General Internal Medicine
•
Hematology
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
Will the treatment for CLL improve or worsen her IgM levels?
Related Questions
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
Does treating CLL reduce the risk of non-melanoma skin cancers?
How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
How do you manage ocular hemorrhages while on acalabrutinib for CLL?
How do you approach c-KIT mutated, core binding factor (CBF) AML?